We can cure some diseases in a single treatment, but scaling those breakthroughs across healthcare is still one of the hardest problems in biotech and pharma.In this episode of An Hour of Innovation, Vit Lyoshin speaks with Tara Austraat-Churik, partner at Blue Matter, and a biotech and pharma expert working on AI-driven drug discovery, clinical development, and bringing new therapies to market. Vit and Tara explore how AI in biotech is reshaping drug discovery, why personalized medicine is closer than ever, and what’s actually preventing these breakthroughs from scaling to reach more patients.They discussed:* How AI is transforming drug discovery and pharma innovation* Why biotech breakthroughs struggle to scale* The true bottleneck: data silos limiting AI in pharma* Why $3M cures exist but remain inaccessible to most* How CRISPR and gene therapy are changing medicine* The reality behind personalized medicine and patient treatment* Digital twins and the future of clinical trials in healthcare* Manufacturing challenges in scaling cell and gene therapies* Why healthcare economics slow down life-saving innovation* Future trends in AI, biotech, and pharma developmentTara Austraat-Churik works at the intersection of biotech, pharma, and AI, helping companies turn scientific breakthroughs into real-world treatments. She focuses on drug discovery, clinical development, and the operational challenges of bringing therapies to patients. Tara has firsthand experience with how decisions are made across the pharma value chain, from early research to market access. She brings a practical perspective on what works, what fails at scale, and why promising innovations often struggle to reach the people who need them most. Her insights help bridge the gap between cutting-edge science and real-world healthcare impact.Timestamps00:00 Introduction02:23 How AI Helps in Biotech05:08 Breakthroughs in Biotech and Pharma08:12 AI's Role in Drug Discovery09:27 Challenges in Implementing AI Solutions13:24 Understanding Cell and Gene Therapy16:58 Current Breakthroughs in Gene Therapy18:30 Scaling Challenges in Cell and Gene Therapies25:28 AI's Impact on Genomics and Gene Therapy27:01 CRISPR: Revolutionizing Research and Treatment28:37 AI-Enhanced Labs: The Future of Discovery29:57 Opportunities for AI in Clinical Trials31:04 Opportunities for AI in Digital Twins 31:41 Opportunities for AI in Decentralized Trials32:51 Opportunities for AI in Medical Writing34:03 How Digital Twin in Medicine Will Work35:07 The Evolution of Personalized Medicine40:34 Tara's Exciting Biotech and Pharma Developments44:59 Innovation Q&AConnect with Tara* Website: https://bluematterconsulting.com/ * LinkedIn: https://www.linkedin.com/in/tchurik/ Support the PodcastIf you enjoy the podcast, you can support it by exploring the tools below.These are affiliate links, meaning the show earns a small commission at no extra cost to you.* Google Workspace: Collaborative way of working in the cloud, from anywhere, on any device.https://referworkspace.app.goo.gl/A7wH* Kit: Email marketing that automates your growth.https://partners.kit.com/xqcc7ca2ahlm* Webflow: Create custom, responsive websites without coding.https://try.webflow.com/0lse98neclhe* Amplemarket: Step into the future of sales: Human + AI. Empower reps, uncover opportunities, and grow revenue.https://grow.amplemarket.com/04e068165684-affiliate For inquiries about sponsoring An Hour of Innovation, email [email protected] Connect with Vit* Substuck: https://anhourofinnovation.substack.com/* LinkedIn: https://www.linkedin.com/in/vit-lyoshin/ * X: https://x.com/vitlyoshin

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related